![Sodium (6R,7R)-7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(hydroxyimino)acetyl]amino]-3-[(E)-[(3…](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fcas-image%2Fthumb-webp%2F313605-sodium-6r-7r-7-2z-2-5-amino-124-thiadiazol-3-yl-2-hydroxyimino-acetyl-amino-3-e-3r-1-5-methyl-2-oxo-13-dioxol-4-yl-methoxy-carbonyl-2-oxo-13-bipyrrolidin-3-ylidene-methyl-8-oxo-5-thia-1-azabicyclo-4-2-0-oct-2-ene-2-carboxylate-1-1.webp&w=3840&q=75)
CAS 252188-71-9: Sodium (6R,7R)-7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(hydroxyimino)acétyl]amino]-3-[(E)-[(3′R)-1′-[[(5-méthyl-2-oxo-1,3-dioxol-4-yl)methoxy]carbonyl]-2-oxo[1,3′-bipyrrolidin]-3-ylidène]méthyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ène-2-carboxylate (1:1)
Description :
La substance chimique connue sous le nom de Sodium (6R,7R)-7-[[[2Z]-2-(5-amino-1,2,4-thiadiazole-3-yl)-2-(hydroxyimino)acétamido]amino]-3-[(E)-[(3′R)-1′-[[(5-méthyl-2-oxo-1,3-dioxole-4-yl)méthoxy]carbonyle]-2-oxo[1,3′-bipyrrolidine]-3-ylidène]méthyle]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ène-2-carboxylate (1:1) est un composé organique complexe caractérisé par sa structure complexe, qui comprend plusieurs groupes fonctionnels tels que les groupes amino, hydroxyimino et carboxylate. Ce composé présente une structure centrale bicyclique, indicative de son activité biologique potentielle. La présence d'un cycle thiadiazole suggère des propriétés antimicrobiennes possibles, tandis que les groupes oxo et dioxole peuvent contribuer à sa réactivité et à sa stabilité. En tant que sel de sodium, il est probablement soluble dans l'eau, ce qui peut améliorer sa biodisponibilité pour des applications pharmaceutiques. La stéréochimie spécifique du composé, désignée par la configuration (6R,7R), peut influencer son interaction avec des cibles biologiques, en faisant un sujet d'intérêt en chimie médicinale et en développement de médicaments. Dans l'ensemble, cette substance illustre la complexité et la diversité des composés organiques synthétiques modernes utilisés dans des contextes thérapeutiques.
Formule :C26H26N8O11S2·Na
InChI :InChI=1S/C26H26N8O11S2.Na/c1-10-14(45-26(41)44-10)8-43-25(40)32-4-3-13(7-32)33-5-2-11(20(33)36)6-12-9-46-22-16(21(37)34(22)17(12)23(38)39)28-19(35)15(30-42)18-29-24(27)47-31-18;/h6,13,16,22,42H,2-5,7-9H2,1H3,(H,28,35)(H,38,39)(H2,27,29,31);/b11-6+,30-15-;/t13-,16-,22-;/m1./s1
Code InChI :InChIKey=BYUIXTXYXHAECA-LCJFHXTKSA-N
SMILES :C(O)(=O)C=1N2[C@@]([C@H](NC(/C(=N\O)/C=3N=C(N)SN3)=O)C2=O)(SCC1/C=C\4/C(=O)N(CC4)[C@H]5CN(C(OCC=6OC(=O)OC6C)=O)CC5)[H].[Na]
Synonymes :- 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(hydroxyimino)acetyl]amino]-3-[(E)-[(3′R)-1′-[[(5-methyl-2-oxo-1,3-dioxol-4-yl)methoxy]carbonyl]-2-oxo[1,3′-bipyrrolidin]-3-ylidene]methyl]-8-oxo-, sodium salt (1:1), (6R,7R)-
- Ro 65-5788
- Sodium (6R,7R)-7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(hydroxyimino)acetyl]amino]-3-[(E)-[(3′R)-1′-[[(5-methyl-2-oxo-1,3-dioxol-4-yl)methoxy]carbonyl]-2-oxo[1,3′-bipyrrolidin]-3-ylidene]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate (1:1)
- 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)(hydroxyimino)acetyl]amino]-3-[(E)-[(3′R)-1′-[[(5-methyl-2-oxo-1,3-dioxol-4-yl)methoxy]carbonyl]-2-oxo[1,3′-bipyrrolidin]-3-ylidene]methyl]-8-oxo-, monosodium salt, (6R,7R)-
- Sodium (6R,7R)-3-((E)-(1-((R)-1-(((5-methyl-2-oxo-1,3-dioxol-4-yl)methoxy)carbonyl)pyrrolidin-3-yl)-2-oxopyrrolidin-3-ylidene)methyl)-7-((Z)-2-(5-amin
- BAL 5788
- Ceftobiprole medocaril sodium
- Ceftobiprole Medocaril Sodium Sterile Powder
Trier par
2 produits concernés.
Ceftobiprole medocaril sodium
CAS :Ceftobiprole medocaril sodium is a broad-spectrum cephalosporin antibiotic, which is a synthetically derived prodrug of ceftobiprole. Upon administration, ceftobiprole medocaril is rapidly converted into its active form, ceftobiprole, by the body's endogenous esterases. The mode of action involves binding to penicillin-binding proteins (PBPs) in the bacterial cell wall, leading to the inhibition of cell wall synthesis and ultimately the death of the bacteria. This action is effective against a wide range of gram-positive and gram-negative bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and penicillin-resistant Streptococcus pneumoniae. Ceftobiprole medocaril sodium is primarily used in the treatment of complex skin and soft tissue infections, as well as community-acquired and hospital-acquired pneumonia. Its broad-spectrum efficacy makes it a critical tool in environments where multi-drug resistant bacterial strains are prevalent. The development of ceftobiprole medocaril was driven by the urgent need for effective antibiotics against resistant pathogens, enabling it to play a vital role in modern infectious disease management and antimicrobial stewardship.Formule :C26H26N8O11S2NaDegré de pureté :Min. 95%Masse moléculaire :713.65 g/molCeftobiprole medocaril sodium
CAS :Ceftobiprole medocaril sodium (BAL5788) is a prodrug of broad-spectrum cephalosporin active against MRSA, VRSA, and resistant streptococci.Formule :C26H25N8NaO11S2Couleur et forme :SolidMasse moléculaire :712.64
